UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Leukemia, 2014-07, Vol.28 (7), p.1529-1536

2014

Volltextzugriff (PDF)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

ESMO open, 2023-08, Vol.8 (4), p.101584-101584, Article 101584

2023

Volltextzugriff (PDF)

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-05, Vol.372 (21), p.2018-2028

2015

Volltextzugriff (PDF)

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

HemaSphere, 2022-06, Vol.6 (Suppl), p.999-1000

2022

Volltextzugriff (PDF)

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.181-181

2012

Volltextzugriff (PDF)

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

Annals of oncology, 2021-09, Vol.32, p.S644-S645

2021

Volltextzugriff (PDF)

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care

Annals of oncology, 2023-10, Vol.34, p.S985-S985

2023

Volltextzugriff (PDF)

P2.12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S363

2023

Volltextzugriff (PDF)

1309P A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-09, Vol.32, p.S1009-S1010

2021

Volltextzugriff (PDF)

133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors

Immuno-oncology technology, 2023-12, Vol.20, p.100605, Article 100605

2023

Volltextzugriff (PDF)

Origin of High-Grade Lymphomas in Richter Syndrome

Leukemia & lymphoma, 1995, Vol.18 (5-6), p.367-372

1995

Volltextzugriff (PDF)

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.527-527

2011

Volltextzugriff (PDF)

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3582-3582

2011

Volltextzugriff (PDF)

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8070-8070

2011

Volltextzugriff (PDF)

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8134-8134

2010

Volltextzugriff (PDF)

A phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20020-20020

2008

Volltextzugriff (PDF)

A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma (NHL)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7528-7528

2006

Volltextzugriff (PDF)

The novel alkylator bendamustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.6564-6564

2005

Volltextzugriff (PDF)

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Blood, 1998-08, Vol.92 (4), p.1317-1323

1998

Volltextzugriff (PDF)

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Blood, 1998-08, Vol.92 (4), p.1317-1323

1998

Volltextzugriff (PDF)

Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma

Blood, 1996-07, Vol.88 (1), p.252-260

1996

Volltextzugriff (PDF)

Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma

Blood, 1996-07, Vol.88 (1), p.252-260

1996

Volltextzugriff (PDF)

Favored use of immunoglobulin VH4 genes in AIDS-associated B-cell lymphoma

Blood, 1996, Vol.88 (1), p.252-260

1996

Volltextzugriff (PDF)

Concomitant gout and rheumatoid arthritis

Journal of rheumatology, 1988-08, Vol.15 (8), p.1307

1988

Volltextzugriff (PDF)

Circulating autoantibodies in patients with pigeon breeder's disease

Allergologia et immunopathologia, 1989-01, Vol.17 (1), p.1

1989

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(174)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care

P2.12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC

1309P A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors

Origin of High-Grade Lymphomas in Richter Syndrome

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

A phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma

A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma (NHL)

The novel alkylator bendamustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma

Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma

Favored use of immunoglobulin VH4 genes in AIDS-associated B-cell lymphoma

Concomitant gout and rheumatoid arthritis

Circulating autoantibodies in patients with pigeon breeder's disease

Suchergebnisse filtern